← 返回

免疫治疗与放疗在癌症治疗中的有效联合

英文原题:Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment.

查看英文原题

Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment.

PubMed 2022/02/07(内容时间) Front Oncol Q2 · IF 3.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

尽管单一肿瘤免疫治疗和放疗已显著提高肿瘤患者的生存率,但在克服肿瘤转移、复发和减少副作用方面仍存在一定局限性。因此,迫切需要探索新的肿瘤治疗方法。放疗与免疫治疗的新型联合方案通过增强免疫系统识别和清除肿瘤细胞的能力,克服肿瘤免疫耐受机制,在提高疗效和减少复发方面显示出前景。纳米材料作为21世纪新型药物递送系统材料,在肿瘤免疫治疗中能够保持药物活性、提高药物靶向性并减少副作用。此外,纳米材料作为放射增敏剂,凭借其光、热、电磁效应等独特性质,在肿瘤放疗中展现出巨大潜力。本文综述了肿瘤免疫治疗和放疗的机制,以及放疗与多种类型免疫治疗的协同作用,包括免疫检查点抑制剂(ICIs)、肿瘤疫苗、过继细胞治疗和细胞因子治疗。最后,我们提出了纳米材料在肿瘤放疗和免疫治疗中的潜力。

展开英文摘要原文

Though single tumor immunotherapy and radiotherapy have significantly improved the survival rate of tumor patients, there are certain limitations in overcoming tumor metastasis, recurrence, and reducing side effects.

Therefore, it is urgent to explore new tumor treatment methods. The new combination of radiotherapy and immunotherapy shows promise in improving therapeutic efficacy and reducing recurrence by enhancing the ability of the immune system to recognize and eradicate tumor cells, to overcome tumor immune tolerance mechanisms. Nanomaterials, as new drug-delivery-system materials of the 21st century, can maintain the activity of drugs, improve drug targeting, and reduce side effects in tumor immunotherapy.

Additionally, nanomaterials, as radiosensitizers, have shown great potential in tumor radiotherapy due to their unique properties, such as light, heat, electromagnetic effects.

Here, we review the mechanisms of tumor immunotherapy and radiotherapy and the synergy of radiotherapy with multiple types of immunotherapies, including immune checkpoint inhibitors (ICIs), tumor vaccines, adoptive cell therapy, and cytokine therapy.

Finally, we propose the potential for nanomaterials in tumor radiotherapy and immunotherapy.

论文信息

作者
Yu S、Wang Y、He P、Shao B、Liu F、Xiang Z、Yang T、Zeng Y
单位
Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China.China
文献类型
综述
期刊
Frontiers in oncology2022
原文标识
PubMed 35198442 · DOI 10.3389/fonc.2022.809304